ReviewMicroorganisms2020
Where do we Stand after Decades of Studying Human Cytomegalovirus?
Review in Microorganisms, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 1 synthesis or guideline pooled it, 89 citations in OpenAlex.
- Research Advances for Virus-vectored Tuberculosis Vaccines and Latest Findings on Tuberculosis Vaccine Development.Frontiers in immunology · 2022Pooled it
- Circular RNAs Associated with Human Cytomegalovirus Infection.Molecules (Basel, Switzerland) · 2026Review
- Integrative immunoinformatics and structural modeling for the rational design of a multi-epitope vaccine candidate against human cytomegalovirus.Scientific reports · 2026Article
- Advances in immunotherapy for cytomegalovirus infection following allogeneic hematopoietic stem cell transplantation.Immunotherapy · 2026Review
- Test, Treat, Repopulate™ method reduces red complex bacteria and stabilizes the oral microbiome.Frontiers in dental medicine · 2026Article
- Progress and prospects for herpesvirus vaccination using gB antigens.Frontiers in immunology · 2026Review
- Clinical characteristics and outcomes of twenty patients with cytomegalovirus-associated anterior uveitis treated with valganciclovir.International ophthalmology · 2025Article
- Article
- Monkeypox Virus Transcriptional Profiles and Host Responses in Skin Lesion Swabs Among Individuals With Human Immunodeficiency Virus.The Journal of infectious diseases · 2025Article
- New Assay Systems to Characterize the Broad-Spectrum Antiherpesviral and Non-Herpesviral Activity of Cyclin-Dependent Kinase (CDK) 8 Inhibitors.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Cytomegalovirus infection in patients attending a tertiary care hospital - single center experience.Iranian journal of microbiology · 2025Article
- Ubiquitination Regulates Reorganization of the Membrane System During Cytomegalovirus Infection.Life (Basel, Switzerland) · 2025Article
- Predictive Factors of Cytomegalovirus Colonic Reactivation in Patients with Active Ulcerative Colitis.Viruses · 2025Article
- Contribution of Sorting Nexin 3 in the Cytomegalovirus Assembly.Biomedicines · 2025Article
- Discovery of Novel Pyrido[2,3-b]Pyrazine Human Cytomegalovirus Polymerase Inhibitors with Broad Spectrum Antiherpetic Activity and Reduced hERG Inhibition.ChemMedChem · 2025Article
- Rare Case of Concomitant Pulmonary Tuberculosis and Cytomegalovirus Infection in an Immunocompetent Patient.Case reports in infectious diseases · 2025Article
- Connecting research and community: a methodological framework for investigating CMV transmission in childcare settings.Frontiers in pediatrics · 2025Article
- Cyclin-Dependent Kinase 8 Represents a Positive Regulator of Cytomegalovirus Replication and a Novel Host Target for Antiviral Strategies.Pharmaceutics · 2024Article
- Serological Screening of TORCH Pathogen Infections in Infertile Women of Childbearing Age in Northwest China.Reproductive sciences (Thousand Oaks, Calif.) · 2024Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Human cytomegalovirus (HCMV), a linear double-stranded DNA betaherpesvirus belonging to the family of Herpesviridae, is characterized by widespread seroprevalence, ranging between 56% and 94%, strictly dependent on the socioeconomic background of the country being considered. Typically, HCMV causes asymptomatic infection in the immunocompetent population, while in immunocompromised individuals or when transmitted vertically from the mother to the fetus it leads to systemic disease with severe complications and high mortality rate. Following primary infection, HCMV establishes a state of latency primarily in myeloid cells, from which it can be reactivated by various inflammatory stimuli. Several studies have shown that HCMV, despite being a DNA virus, is highly prone to genetic variability that strongly influences its replication and dissemination rates as well as cellular tropism. In this scenario, the few currently available drugs for the treatment of HCMV infections are characterized by high toxicity, poor oral bioavailability, and emerging resistance. Here, we review past and current literature that has greatly advanced our understanding of the biology and genetics of HCMV, stressing the urgent need for innovative and safe anti-HCMV therapies and effective vaccines to treat and prevent HCMV infections, particularly in vulnerable populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.